SCHEMBL14158705

SCHEMBL14158705

Cc1c(-c2ccc3c(c2)N(C)CC3)c2c(NS(=O)(=O)c3ccn(C)n3)ccnc2n1C

nearest known ligand 0.69

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ CYBB P04839 2/20 0.69
▸ NOTUM Q6P988 1/20 0.33
▸ NLRP3 Q96P20 1/20 0.33
▸ PIK3C3 Q8NEB9 1/20 0.32
▸ CCR2 P41597 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14158922 0.90 CYBB (0.72) CYBBNOTUMNLRP3PIK3C3
SCHEMBL14158698 0.86 CYBB (0.52) CYBBNOTUM
SCHEMBL14158858 0.86 CYBB (0.64) CYBBNOTUMNLRP3PIK3C3CCR2
SCHEMBL14158648 0.86 CYBB (0.58) CYBBNLRP3PIK3C3CCR2
SCHEMBL14158539 0.84 CYBB (0.83) CYBBNOTUMNLRP3PIK3C3CCR2
SCHEMBL14158678 0.83 CYBB (0.66) CYBBNOTUMNLRP3PIK3C3CCR2
SCHEMBL14158946 0.82 CYBB (0.70) CYBBNOTUMNLRP3
SCHEMBL14158596 0.82 CYBB (1.00) CYBBNOTUMNLRP3PIK3C3CCR2
SCHEMBL14158872 0.81 CYBB (0.78) CYBBNOTUMNLRP3CCR2
SCHEMBL14158776 0.80 CYBB (0.45) CYBBPIK3C3CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877742-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) 2014-11-04 — — US disclosed
US-8877742-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) 2014-11-04 — — US disclosed
US-8877742-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) 2014-11-04 — — US disclosed
US-20140155375-A1 NOVEL COMPOUNDS GlaxoSmithKline Interllectual Property Limited (GB) 2014-06-05 — — US disclosed
US-20140155375-A1 NOVEL COMPOUNDS GlaxoSmithKline Interllectual Property Limited (GB) 2014-06-05 — — US disclosed
US-20140155375-A1 NOVEL COMPOUNDS GlaxoSmithKline Interllectual Property Limited (GB) 2014-06-05 — — US disclosed
EP-2717694-A1 NOVEL COMPOUNDS GlaxoSmithKline Intellectual Property Limited (GB) 2014-04-16 — — EP disclosed
WO-2012170752-A1 NOVEL COMPOUNDS GLAXO WELLCOME MANUFACTURING PTE LTD (SG) 2012-12-13 — — WO disclosed
WO-2012170752-A1 NOVEL COMPOUNDS GLAXO WELLCOME MANUFACTURING PTE LTD (SG) 2012-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155375-A1 NOVEL COMPOUNDS CYBB, NOX1, NOX4 CYBB 1/4885NOTUM 2865/4885NLRP3 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback